Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Medullary thyroid cancer: monitoring and therapy Ball DWEndocrinol Metab Clin North Am 2007[Sep]; 36 (3): 823-37, viiiThis article summarizes the clinical features and molecular pathogenesis of medullary thyroid cancer (MTC) and focuses on the current use of molecular, biochemical, and imaging disease markers as a basis for selection of appropriate therapy. Clinicians treating patients who have MTC face the following challenges: (1) distinguishing MTC as early as possible from benign nodular disease and differentiated thyroid cancer to choose the appropriate initial surgery, (2) managing low-level residual cancer in otherwise asymptomatic individuals, and (3) treating progressive metastatic disease. Early clinical trials using small molecules targeting Ret or vascular endothelial growth factor receptors suggest that such approaches could be effective and well tolerated. This article highlights early progress in targeted therapy of MTC and significant challenges in disease monitoring to appropriately select and evaluate patients being treated with these therapies.|Angiogenesis Inhibitors/therapeutic use[MESH]|Biomarkers/blood[MESH]|Carcinoma, Medullary/*diagnosis/genetics/radiotherapy/*therapy[MESH]|Diagnostic Imaging[MESH]|Genetic Markers[MESH]|Humans[MESH]|Lymph Node Excision[MESH]|Proto-Oncogene Proteins c-ret/antagonists & inhibitors[MESH]|Thyroid Neoplasms/*diagnosis/genetics/radiotherapy/*therapy[MESH]|Thyroidectomy[MESH] |
